Haverford Trust Co. Sells 8,978 Shares of Pfizer Inc. (NYSE:PFE)

Haverford Trust Co. trimmed its position in Pfizer Inc. (NYSE:PFE) by 2.0% in the third quarter, HoldingsChannel reports. The firm owned 449,278 shares of the biopharmaceutical company’s stock after selling 8,978 shares during the quarter. Haverford Trust Co.’s holdings in Pfizer were worth $16,143,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Morgan Stanley lifted its stake in Pfizer by 2.4% in the 2nd quarter. Morgan Stanley now owns 46,536,777 shares of the biopharmaceutical company’s stock worth $2,015,972,000 after purchasing an additional 1,071,897 shares in the last quarter. Fisher Asset Management LLC lifted its stake in Pfizer by 2.6% in the 3rd quarter. Fisher Asset Management LLC now owns 45,291,398 shares of the biopharmaceutical company’s stock worth $1,627,320,000 after purchasing an additional 1,158,147 shares in the last quarter. Nuveen Asset Management LLC lifted its stake in Pfizer by 2,240.5% in the 2nd quarter. Nuveen Asset Management LLC now owns 36,086,254 shares of the biopharmaceutical company’s stock worth $1,563,256,000 after purchasing an additional 34,544,423 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Pfizer by 2.5% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 35,948,881 shares of the biopharmaceutical company’s stock worth $1,557,306,000 after purchasing an additional 868,839 shares in the last quarter. Finally, California Public Employees Retirement System lifted its stake in Pfizer by 5.3% in the 2nd quarter. California Public Employees Retirement System now owns 23,186,244 shares of the biopharmaceutical company’s stock worth $1,004,428,000 after purchasing an additional 1,159,857 shares in the last quarter. 71.52% of the stock is owned by institutional investors and hedge funds.

PFE has been the topic of several recent analyst reports. DZ Bank upgraded shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 target price on the stock in a research note on Wednesday, August 28th. Bank of America assumed coverage on shares of Pfizer in a research report on Wednesday, October 16th. They set a “neutral” rating and a $37.00 price objective on the stock. JPMorgan Chase & Co. restated a “neutral” rating on shares of Pfizer in a research report on Tuesday, October 29th. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price objective on the stock in a research report on Tuesday, October 1st. Finally, ValuEngine upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Nine analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $44.02.

In other Pfizer news, major shareholder Pfizer Inc bought 50,000 shares of Pfizer stock in a transaction that occurred on Tuesday, September 17th. The shares were bought at an average price of $18.00 per share, with a total value of $900,000.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Scott Gottlieb purchased 3,000 shares of the business’s stock in a transaction on Friday, August 23rd. The stock was purchased at an average cost of $34.72 per share, for a total transaction of $104,160.00. Following the acquisition, the director now owns 3,000 shares in the company, valued at $104,160. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by company insiders.

Shares of Pfizer stock traded up $0.14 on Friday, hitting $37.05. 25,261,807 shares of the company traded hands, compared to its average volume of 16,850,170. The firm’s 50-day simple moving average is $36.61 and its 200 day simple moving average is $39.27. The company has a current ratio of 1.47, a quick ratio of 1.21 and a debt-to-equity ratio of 0.60. The company has a market cap of $207.30 billion, a P/E ratio of 12.35, a P/E/G ratio of 2.11 and a beta of 0.67. Pfizer Inc. has a 12-month low of $33.97 and a 12-month high of $46.47.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.13. Pfizer had a net margin of 30.57% and a return on equity of 28.61%. The company had revenue of $12.68 billion for the quarter, compared to analyst estimates of $12.37 billion. During the same quarter last year, the firm earned $0.78 EPS. The firm’s quarterly revenue was down 4.6% compared to the same quarter last year. Analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a dividend yield of 3.89%. The ex-dividend date of this dividend is Thursday, November 7th. Pfizer’s dividend payout ratio is currently 48.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: Trading Stocks – What are percentage gainers?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.